194 related articles for article (PubMed ID: 37787401)
1. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.
Hou W; Gad SA; Ding X; Dhanarajan A; Qiu W
Mol Carcinog; 2024 Jan; 63(1):173-189. PubMed ID: 37787401
[TBL] [Abstract][Full Text] [Related]
2. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.
Hou W; Bridgeman B; Malnassy G; Ding X; Cotler SJ; Dhanarajan A; Qiu W
Hepatol Commun; 2022 Jul; 6(7):1786-1802. PubMed ID: 35238496
[TBL] [Abstract][Full Text] [Related]
3. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
4. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
[TBL] [Abstract][Full Text] [Related]
5. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E₂ receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells.
Bai X; Wang J; Zhang L; Ma J; Zhang H; Xia S; Zhang M; Ma X; Guo Y; Rong R; Cheng S; Shu W; Wang Y; Leng J
Int J Oncol; 2013 May; 42(5):1833-41. PubMed ID: 23525457
[TBL] [Abstract][Full Text] [Related]
7. METTL3-m
Wang L; Yang Q; Zhou Q; Fang F; Lei K; Liu Z; Zheng G; Zhu L; Huo J; Li X; Peng S; Kuang M; Lin S; Huang M; Xu L
Cancer Lett; 2023 Apr; 559():216122. PubMed ID: 36898427
[TBL] [Abstract][Full Text] [Related]
8. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma.
Liu X; Song X; Zhang J; Xu Z; Che L; Qiao Y; Ortiz Pedraza Y; Cigliano A; Pascale RM; Calvisi DF; Liu Y; Chen X
Cancer Med; 2018 Dec; 7(12):6170-6181. PubMed ID: 30370649
[TBL] [Abstract][Full Text] [Related]
10. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
11. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang M; Long J; Yao Z; Zhao Y; Zhao Y; Liao J; Lei K; Xiao H; Dai Z; Peng S; Lin S; Xu L; Kuang M
Cancer Res; 2023 Jan; 83(1):89-102. PubMed ID: 36102722
[TBL] [Abstract][Full Text] [Related]
12. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
13. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
Guo J; Zhao J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
[TBL] [Abstract][Full Text] [Related]
14. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway.
Yu M; Zou Q; Wu X; Han G; Tong X
Biomed Pharmacother; 2017 Nov; 95():1844-1852. PubMed ID: 28968929
[TBL] [Abstract][Full Text] [Related]
15. WNK1-OSR1 Signaling Regulates Angiogenesis-Mediated Metastasis towards Developing a Combinatorial Anti-Cancer Strategy.
Hou CY; Ma CY; Lin YJ; Huang CL; Wang HD; Yuh CH
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292952
[TBL] [Abstract][Full Text] [Related]
16. Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma.
Leung CON; Yang Y; Leung RWH; So KKH; Guo HJ; Lei MML; Muliawan GK; Gao Y; Yu QQ; Yun JP; Ma S; Zhao Q; Lee TKW
Nat Commun; 2023 Oct; 14(1):6699. PubMed ID: 37872167
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of focal adhesion kinase by 14-3-3ε via NFκB activation in hepatocellular carcinoma.
Ko BS; Jan YJ; Chang TC; Liang SM; Chen SC; Liu TA; Wu YM; Wang J; Liou JY
Anticancer Agents Med Chem; 2013 May; 13(4):555-62. PubMed ID: 22934705
[TBL] [Abstract][Full Text] [Related]
18. Degradation of FAK-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma.
Zhang X; Li S; Song M; Chen Y; Chang L; Liu Z; Dai H; Wang Y; Yang G; Jiang Y; Lu Y
Oncol Res; 2024; 32(4):679-690. PubMed ID: 38560575
[TBL] [Abstract][Full Text] [Related]
19. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
20. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.
Fan M; Chen Z; Shao W; Chen Y; Lin Z; Yi C; Li Y; Lu L; Zhou Y; Lin J
Acta Biochim Biophys Sin (Shanghai); 2023 Jul; 55(9):1479-1486. PubMed ID: 37434430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]